Thermo Fisher agreed to acquire Patheon for $35.00/share in cash, total enterprise value approximately $7.2B (including ~$2.0B assumed net debt). The deal added a leading pharmaceutical CDMO with $1.9B fiscal 2016 revenue to Thermo Fisher's Laboratory Products and Services Segment, with expected $120M synergies by year three. Closed August 29, 2017.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedMay 15, 2017
ClosedAug 29, 2017
Deal value$7.2B
Deal typeAcquisition/Merger
Therapeutic areaPharmaceutical contract development and manufacturing
IndicationsPharmaceutical contract development and manufacturing
Key assetsCDMO services platform (drug substance, drug product, formulation)
MechanismContract development and manufacturing organization platform